The Outlook for Cardiovascular Risk Factors: Epidemiology, market and
pipeline analysis, evaluates current and future growth prospects for pharma
companies to 2008 in five major cardiovascular risk factors that can be
moderated by pharmacotherapy; hypertension, dyslipidemia, diabetes, obesity and
smoking. Cumulatively, the value of these markets was approximately $66bn in
2002 or around one-fifth of the global pharmaceutical market. In the US alone,
the direct and indirect costs of cardiovascular disease (CVD) and stroke in 2003
are estimated at almost $352bn. Reducing these costs by appropriately treating
cardiovascular risk factors has become a major focus of the pharmaceutical
industry and healthcare payors.
This report sets out to define cardiovascular risk factors and how
identifying links to them sooner, will lead to a decline in CVD, resulting in
massive cost savings for both pharma companies and healthcare payors. Treating
risk factors is preventive medicine at its most challenging and this report
provides insights into the risk factors that pharma companies need to overcome
this battle - it can be won...let this report help you.
View Cart
